EcoDrugPlus

Neurotrophic Tyrosine Kinase, Receptor, Type 2

Ensembl ID : ENSMSIG00000020750
Gene Symbol: NTRK2
1 Cross references
301 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3

Ensembl ID : ENSMSIG00000018687
Gene Symbol: NTRK3
1 Cross references
284 Possible Orthologues:

Nicastrin

Ensembl ID : ENSMSIG00000007600
Gene Symbol: NCSTN
1 Cross references
218 Possible Orthologues:

Nischarin

Ensembl ID : ENSMSIG00000029583
Gene Symbol: NISCH
1 Cross references
224 Possible Orthologues:

Nitric Oxide Synthase 2, Inducible

Ensembl ID : ENSMSIG00000009679
Gene Symbol: NOS2
1 Cross references
178 Possible Orthologues:

Notch 1

Ensembl ID : ENSMSIG00000028222
Gene Symbol: NOTCH1
1 Cross references
288 Possible Orthologues:

Notch 3

Ensembl ID : ENSMSIG00000005867
Gene Symbol: NOTCH3
1 Cross references
215 Possible Orthologues:

Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells 1, P105

Ensembl ID : ENSMSIG00000025165
Gene Symbol: NFKB1
1 Cross references
215 Possible Orthologues:

Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells 2, P49/p100

Ensembl ID : ENSMSIG00000011557
Gene Symbol: NFKB2
1 Cross references
139 Possible Orthologues:

Nuclear Factor, Erythroid Derived 2, Like 2

Ensembl ID : ENSMSIG00000005673
Gene Symbol: NFE2L2
1 Cross references
231 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 2

Ensembl ID : ENSMSIG00000009948
Gene Symbol: NR1H2
1 Cross references
320 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSMSIG00000020950
Gene Symbol: NR1H3
1 Cross references
406 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).